CALC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 53.30%

Insider Buying (Last 12 Months): $3,508,426.87

Insider Selling (Last 12 Months): $0.00

CalciMedica Insider Trading History Chart

CalciMedica Share Price & Price History

^$3.94

▲ +0.06 (1.55%)

As of 07/26/2024 01:00 AM ET

Days: 30 | 90 | 365

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

CalciMedica Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/27/2024	Eric W Roberts	Insider	Buy	5,000	$3.22	$16,100.00	10,223
6/27/2024	Robert N Wilson	Director	Buy	8,443	$3.23	$27,270.89	258,918
4/1/2024	Eric W Roberts	Insider	Buy	746	$3.90	$2,909.40	36,640
1/23/2024	Fred A Middleton	Director	Buy	679,384	$3.70	$2,513,720.80	946,744
1/23/2024	Sanderling Venture Partners Vi	Major Shareholder	Buy	243,356	$3.70	$900,417.20	946,744
12/11/2023	Robert N Wilson	Director	Buy	506	$3.30	$1,669.80	182,161
11/6/2023	A. Rachel Leheny	CEO	Buy	2,440	$3.12	$7,612.80	16,840
11/6/2023	Eric W Roberts	Insider	Buy	2,400	$3.12	$7,488.00	35,894
11/3/2023	A. Rachel Leheny	CEO	Buy	5,000	$2.85	$14,250.00	14,400
11/3/2023	Eric W Roberts	Insider	Buy	3,200	$2.80	$8,960.00	16,587
8/25/2023	Eric W Roberts	Insider	Buy	736	$3.18	$2,340.48	5,000
8/21/2023	Eric W Roberts	Insider	Buy	1,750	$3.25	$5,687.50	3,550
6/26/2023	Eric W Roberts	Insider	Buy	1,200	$3.70	$4,440.00	13,387
6/23/2023	Eric W Roberts	Insider	Buy	500	$3.35	$1,675.00	16,185

J.P. Morgan’s DIRE Warning

From Behind the Markets | Ad

When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."

Click here to see why Wall Street is in PANIC mode >>>

SEC Filings (Institutional Ownership Changes) for CalciMedica (NASDAQ:CALC)

Institutional Buying and Selling by Quarter

CalciMedica Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/23/2024	BML Capital Management LLC	160,424	$0.67M	0.4%	+10.3%	1.494%
2/2/2024	Meritage Portfolio Management	46,000	$0.13M	0.0%	+360.0%	0.810%
1/30/2024	BML Capital Management LLC	145,424	$0.42M	0.3%	+63.8%	2.560%
12/7/2023	Hudson Bay Capital Management LP	166,857	$0.43M	0.0%	N/A	2.938%
7/31/2023	Meritage Portfolio Management	10,000	$40K	0.0%	N/A	0.177%
7/24/2023	BML Capital Management LLC	88,781	$0.36M	0.3%	N/A	1.568%

Data available starting January 2016

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Today's Range

Now: $3.94

$3.91

$3.99

50 Day Range

MA: $4.82

$3.15

$5.69

52 Week Range

Now: $3.94

$1.75

$8.38

Volume

1,922 shs

Average Volume

28,371 shs

Market Capitalization

$42.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Who are the company insiders with the largest holdings of CalciMedica?: CalciMedica's top insider investors include:
Fred A Middleton (Director)
Sanderling Venture Partners Vi (Major Shareholder)
Robert N Wilson (Director)
Eric W Roberts (Insider)
A Rachel Leheny (CEO)
Learn More about top insider investors at CalciMedica.